Brian O'Callaghan, ObsEva CEO
July 27, 2022 06:55 AM EDTUpdated 07:44 AM
R&D

Ob­sE­va im­plodes on warn­ing that the FDA has set up a road­block for its flag­ship drug

John Carroll

Editor & Founder

Just weeks af­ter scor­ing an ap­proval for its flag­ship drug in Eu­rope, Ob­sE­va has run in­to a reg­u­la­to­ry mael­strom in the US that has evis­cer­at­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times